Abstract

Cancer is a multifactorial disease and the second leading cause of death worldwide. Diverse factors induce carcinogenesis, such as diet, smoking, radiation, and genetic defects. The phosphatidylinositol 3-kinase (PI3Kα) has emerged as an attractive target for anticancer drug design. Eighteen derivatives of N-phenyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamide were synthesized and characterized using FT-IR, NMR (1H and 13C), and high-resolution mass spectra (HRMS). The series exhibited distinct antiproliferative activity (IC50 µM) against human epithelial colorectal adenocarcinoma (Caco-2) and colon carcinoma (HCT-116) cell lines, respectively: compounds 16 (37.4, 8.9 µM), 18 (50.9, 3.3 µM), 19 (17.0, 5.3 µM), and 21 (18.9, 4.9 µM). The induced-fit docking (IFD) studies against PI3Kαs showed that the derivatives occupy the PI3Kα binding site and engage with key binding residues.

Highlights

  • The emergence of cancer cases continues to rise worldwide

  • Applying pharmacophore modeling and database screening against the national cancer institute (NCI) database [17], we previously revealed N-benzyl-4-hydroxy-2-quinolone

  • Thin-layer chromatography (TLC) application was recruited to monitor the reaction progress; the absence of a spot belonging to 3 highlighted the completeness of the reaction

Read more

Summary

Introduction

The emergence of cancer cases continues to rise worldwide. A group of diseases, is considered a prevalent health problem and cause of death. Cancer is uncontrolled cell proliferation accompanied with invasion to other body organs [1]. Multiple factors induce cancer occurrence, such as smoking, diet, radiation, viral infections, and genetic disorders [2,3,4,5]. Phosphatidylinositol 3-kinases (PI3Ks) catalyze the phosphorylation of phosphatidylinositol on the 3-OH group of inositol ring generating phosphatidylinositol. PIP3 invoke downstream effectors and signaling proteins such as protein kinase B (AKT) inducing cell growth and multiplication [6,7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call